64Z Stock Overview
A biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Keymed Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.50 |
| 52 Week High | HK$6.55 |
| 52 Week Low | HK$3.24 |
| Beta | -0.067 |
| 11 Month Change | -11.76% |
| 3 Month Change | 25.70% |
| 1 Year Change | -27.42% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 80.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 64Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.2% | -0.7% | -0.02% |
| 1Y | -27.4% | -17.2% | 8.2% |
Return vs Industry: 64Z underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 64Z underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 64Z volatility | |
|---|---|
| 64Z Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 64Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 64Z's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 1,116 | Bo Chen | www.keymedbio.com |
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD.
Keymed Biosciences Inc. Fundamentals Summary
| 64Z fundamental statistics | |
|---|---|
| Market cap | €1.30b |
| Earnings (TTM) | -€98.48m |
| Revenue (TTM) | €10.82m |
120.0x
P/S Ratio-13.2x
P/E RatioIs 64Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 64Z income statement (TTM) | |
|---|---|
| Revenue | CN¥81.65m |
| Cost of Revenue | CN¥25.60m |
| Gross Profit | CN¥56.06m |
| Other Expenses | CN¥799.13m |
| Earnings | -CN¥743.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.70 |
| Gross Margin | 68.65% |
| Net Profit Margin | -910.03% |
| Debt/Equity Ratio | 27.3% |
How did 64Z perform over the long term?
See historical performance and comparison